Results 261 to 270 of about 24,235,259 (324)

Disproportionality Analysis of Hematologic Adverse Event Signals Associated with Venetoclax in Combination with Senescence-Inducing Chemotherapy. [PDF]

J Clin Med
Saleh T, Ramadan M, Alsoud A, Al Shboul S.   +3 more
europepmc   +1 more source

Long-term safety evaluation of mirtazapine: A real-world pharmacovigilance study based on the FAERS database. [PDF]

PLoS One
Zhao K, Liu J.
europepmc   +1 more source

Potential impact of nicorandil on the pharmacodynamics of anti-angiogenic agents. [PDF]

Sci Rep
Pan C, Onda K, Ebina K, Kawakami M, Yokosawa M, Hirano T, Suzuki K.   +6 more
europepmc   +1 more source

Identification of Drug Repurposing Opportunities of Immunomodulatory Drugs for Inflammatory Bowel Disease Through Inverse Pharmacovigilance Signal Detection in the FAERS Database. [PDF]

J Clin Med
Đogatović K, Vučićević K, Kovačević M, Ćulafić M, Miljković B, Kovačević SV.   +5 more
europepmc   +1 more source

Metabolic mimicry of perioral myoclonia with absences: A signature of thalamocortical instability in childhood‐onset ornithine transcarbamylase deficiency

Epileptic Disorders, EarlyView.
José Augusto Bragatti, Letícia Grigoletto   +1 more
wiley   +1 more source

Sex-specific adverse event profiles of PDE4 inhibitors: a comparative big-data pharmacovigilance study of apremilast, crisaborole, and roflumilast in FAERS (2004-2025). [PDF]

Front Pharmacol
Huang B, Gu S, Wang S, Ma Y, Zhou Y, Wang W.   +5 more
europepmc   +1 more source

The Real-World Endocrine Toxicity Profile of ICIs, VEGFR-TKIs, and Their Combination: Analysis of the FDA Adverse Event Reporting System (FAERS) Database. [PDF]

Oncol Res
Marrano N, Caporusso M, Matino C, Caruso I, Ganini C, Rizzo M, Di Gioia L, Cignarelli A, Perrini S, Laviola L, Porta C, Giorgino F, Natalicchio A.   +12 more
europepmc   +1 more source